Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-12. Numbers and descriptions here follow the published literature rather than marketing material.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
== External links == Lisa Cross Official Biography Lisa Cross Biography Archived 10 August 2012 at the Wayback Machine 2009 UKBFF Hercules Competition Photographs 2009 NABBA England Results Archived 18 September 2010 at the Wayback Machine - Miss Physique, 2nd 2009 NABBA Universe Results Archived 18 September 2010 at the Wayback Machine - Miss Physique, 2nd 2010 UKBFF British Championships Results Archived 22 November 2010 at the Wayback Machine - Ladies Physique, 1st FLEX Magazine (British Edition, April 2010) Archived 16 November 2010 at the Wayback Machine
But as season three reminds us, the punches hit harder when there's something worth fighting for." Jake Kleinman was positive towards the season for his review at, Inverse though considered it unnecessary: "Maybe The Boys was built for Trump, and without his constant presence, it feels less necessary. Maybe Marvel is less untouchable than it was a few years ago, and The Boys no longer feels like a scrappy parody punching up but more like Amazon punching down." Inkoo Kang from The Washington Post praised the show for its themes and performances and suggested: "It's a sturdily built season, but it might make you miss the show at its full strength."
Beaches protected from tides and storms by coral reefs are often the best places for housing in tropical countries. Reefs are an important food source for low-technology fishing, both on the reefs themselves and in the adjacent seas. However, despite their great productivity, reefs are vulnerable to over-fishing, because much of the organic carbon they produce is exhaled as carbon dioxide by organisms at the middle levels of the food chain and never reaches the larger species that are of interest to fishermen. Tourism centered on reefs provides much of the income of some tropical islands, attracting photographers, divers and sports fishermen. However, human activities damage reefs in several ways: mining for construction materials; pollution, including large influxes of fresh water from storm drains; commercial fishing, including the use of dynamite to stun fish and the capture of young fish for aquariums; and tourist damage caused by boat anchors and the cumulative effect of walking on the reefs. Coral, mainly from the Pacific Ocean has long been used in jewellery, and demand rose sharply in the 1980s. Some large jellyfish species of the Rhizostomeae order are commonly consumed in Japan, Korea and Southeast Asia. In parts of the range, fishing industry is restricted to daylight hours and calm conditions in two short seasons, from March to May and August to November. The commercial value of jellyfish food products depends on the skill with which they are prepared, and "Jellyfish Masters" guard their trade secrets carefully.
=== Plot === Opposing Force opens with Shephard riding on a V-22 Osprey with his squad. His squad discuss their deployment, somewhat irritated that they have not been told what they are being deployed for. However, as they are nearing their landing zone at Black Mesa, airborne alien creatures attack the Osprey formation, causing Shephard's Osprey to crash land. Shephard regains consciousness in a Black Mesa medical bay, tended to by the science team, learning that the Marines are being steadily beaten by the alien forces from Xen and orders have come through to pull out. Consequently, Shephard departs to reach an extraction point and escape the facility. However, Shephard is prevented from reaching the extraction point by the enigmatic G-Man, resulting in the evacuation craft leaving without him. Other Marines who have also been left behind team up with Shephard and attempt to reach another extraction point near Black Mesa's Lambda Complex, but en route they come under attack from black operations units seeking to thoroughly contain the situation and eliminate all survivors. Shephard makes it to the Lambda Complex alive, and briefly sees Gordon Freeman as the latter teleports to Xen in the final stages of Half-Life. To escape the teleportation chamber, Shephard is forced to enter a separate portal, briefly taking him to Xen before depositing him in an entirely different area of the facility.
==== H2 gas ==== The δD of atmospheric H2 is around +180‰, the biggest δD known for natural terrestrials (mole fraction 2H: 183.8 ppm). The δD of natural gas from a Kansas well is around −836‰ (mole fraction 2H: 25.5 ppm) In electrolysis of water, hydrogen gas is produced at the cathode, but incomplete electrolysis of water may cause isotopic fractionation leading to enrichment of 2H in the sample water and the production of hydrogen gas with deuterium components.
Sources: en.wikipedia.org
The transition to democracy took place in the early years of his reign, making Spain no longer the only non-communist dictatorship left in Europe. The new king assumed the project of the reformist sector of Franco's political elite that, facing the conservatives, defended the need to introduce gradual changes in the fundamental laws so that the new monarchy would be accepted in Europe as a whole. This project was the one that his first government tried to implement, and it was presided by Carlos Arias Navarro, who had already headed the last government of General Franco. However, in view of the incapacity demonstrated by Arias Navarro, Juan Carlos appointed in July 1976 the Francoist "reformist" Adolfo Suárez as the new Head of Government to lead the process of transition to democracy without any "rupture" with the "previous regime". This is how the Political Reform Act came about, which was approved by the Francoist Cortes and revalidated in the referendum of December 1976. According to this new fundamental law, free elections to democratically elected Cortes were to be called. Suarez's problem was to get the "controlled" transition process established in the Political Reform Act accepted by the democratic opposition, since the latter, in exchange for abandoning the "democratic rupture" and participating in the elections, demanded that Franco's institutions be dismantled and that all parties without exception ─ including the Communist Party of Spain ─ be legalized.
GeneDx's biopharma business focuses on leveraging GeneDx Infinity to provide partners with access to molecularly confirmed genomic data, longitudinal patient information, and curated phenotypic data to support drug discovery, clinical development, real-world evidence generation and other therapeutic development needs. By combining large-scale sequencing data with clinical and phenotypic context, the company aims to accelerate rare disease research and improve the efficiency and success rate of biopharmaceutical development programs.
EDC is a water-soluble carbodiimide reagent used for a wide range of purposes. Apart from uses similar to those of DCC and DIC, it is also used for various biochemical purposes as a crosslinker or chemical probe.
Smoking of opium came on the heels of tobacco smoking and may have been encouraged by a brief ban on the smoking of tobacco by the Ming emperor. The prohibition ended in 1644 with the coming of the Qing dynasty, which encouraged smokers to mix in increasing amounts of opium. In 1705, Wang Shizhen wrote: "nowadays, from nobility and gentlemen down to slaves and women, all are addicted to tobacco". Tobacco in that time was frequently mixed with other herbs (this continues with clove cigarettes to the modern day), and opium was one component in the mixture. Tobacco mixed with opium was called madak (or madat) and became popular throughout China and its seafaring trade partners (such as Taiwan, Java, and the Philippines) in the 17th century. In 1712, Engelbert Kaempfer described addiction to madak: "No commodity throughout the Indies is retailed with greater profit by the Batavians than opium, which [its] users cannot do without, nor can they come by it except it be brought by the ships of the Batavians from Bengal and Coromandel." Fueled in part by the 1729 ban on madak, which at first effectively exempted pure opium as a potentially medicinal product, the smoking of pure opium became more popular in the 18th century. In 1736, the smoking of pure opium was described by Huang Shujing, involving a pipe made from bamboo rimmed with silver, stuffed with palm slices and hair, fed by a clay bowl in which a globule of molten opium was held over the flame of an oil lamp.
they are easy to consume and as such are convenient for such patients as "the elderly, stroke victims, bedridden patients, patients affected by kidney failure, and people who refuse to swallow, such as pediatric, geriatric, and psychiatric patients"; increased bioavailability (rapid absorption) due to pregastric absorption; don't require water to consume and thus suitable for "patient compliant for disabled, bedridden patients, and for travelers and busy people who do not always have access to water"; good mouth feel; improved safety due to low risk of choking or suffocation during oral administration.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.